Airsculpt Technologies Inc(AIRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:57 PM ET (Korea 9/12 05:57)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.18 | Insider Own | 85.49% | Shs Outstand | 71.5M | Perf Week | -4.72% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 43.75% | Insider Trans | 1.07% | Shs Float | 10.5M | Perf Month | -25.54% |
| Enterprise Value | 0.23B | PEG | - | EPS next Q | -0.03 | Inst Own | 27.43% | Short Float | 28.72% | Perf Quarter | -54.77% |
| Income | -0.01B | P/S | 1.16 | EPS this Y | -60% | Inst Trans | -2.83% | Short Ratio | 4.19 | Perf Half Y | 11.01% |
| Sales | 0.15B | P/B | 1.65 | EPS next 5Y | 11.21% | ROA | -5.99% | Short Interest | 3.00M | Perf YTD | 22.22% |
| Book/sh | 1.47 | P/C | 9.27 | EPS past 3/5Y | 9.87% - | ROE | -11.98% | 52W High | -79.83% ($12.00) | Perf Year | -61.65% |
| Cash/sh | 0.26 | P/FCF | 229.57 | Sales past 3/5Y | -3.47% 19.32% | ROIC | -7.45% | 52W Low | 60.26% ($1.51) | Perf 3Y | -69.09% |
| Dividend Est. | - | EV/EBITDA | 20.33 | EPS Y/Y TTM | 26.89% | Gross Margin | 51.6% | Volatility(W/M) | 9.24% 8.52% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.51 | Sales Y/Y TTM | -8.71% | Oper. Margin | -0.72% | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | 2022/8/25 | Quick Ratio | 0.79 | EPS Q/Q | -58.59% | Profit Margin | -7.79% | RSI (14) | 34.79 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.79 | Sales Q/Q | -2.53% | SMA20 | -9.61% ($2.68) | Beta | 2.27 | Target Price | $4.5 |
| Payout | - | Debt/Eq | 0.68 | Earnings | 2026/8/10 | SMA50 | -34.61% ($3.7) | Rel Volume | 1.25 | Prev Close | $2.4 |
| Employees | 363 | LT Debt/Eq | 0.5 | EPS/Sales Surpr. | -33.33% -2.8% | SMA200 | -26.05% ($3.27) | Avg Volume(3M) | 0.72M | Price | $2.42 |
| IPO | 2021/10/29 | Option/Short | Yes/Yes | Trades | 6402 | Volume | 893,842 | Change | 0.83% |
Company
AIRS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💎 This is a specialized medical company that offers premium body contouring and fat removal services. Leveraging its proprietary patented technology, AirSculpt®, the company provides safe and effective procedures without general anesthesia, actively targeting the high-end body contouring market in the US and other regions.
Over the past 1 year, on the lower side
80% below its 1-year high.
AIRS has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -60.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -69.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 27.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAS 0.00%
GLX 0.00%
HDG 0.00%
HONG 0.00%It ranks #4 in the industry
Based on market cap of $174M.
AIRS $174M PER -
HCA $92B PER 14.3
THC $21B PER 10.2
EHC $12B PER 19.8
FAQ
What kind of company is AIRS?
AIRS belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of AIRS?
The market cap of AIRS is approximately $174M, ranking 4,217 within its sector.
What is the 52-week high and low for AIRS?
AIRS has recorded a 52-week high of $12.00 and a low of $1.51.
